Kornimate/medical-research-clean huggingface dataset:
post-stroke immunological changes in young stroke patients

Conditions: Stroke, Ischemic; Cognitive Decline

Summary: in the present study, the investigators aim to elucidate the role of t-cells on cognitive decline in younger stroke patients, using repeated cognitive testing, brain imaging, and immunological analyses in the first 6 month after stroke. the examiners will investigate (i) the extent and duration of stroke-induced changes in t cell function within the peripheral blood of patients; and (ii) post-stroke cognitive functions.

demands from society on stroke patients of younger age are in most cases higher than for elderly stroke patients, because of occupational obligations and often their role as a caregiver for a young family. for example, return to their former workplace may be impossible even if cognitive deficits, e.g., in the memory domain, are only "minor" according to standardized tests. thus, cognitive function after stroke is of utmost importance for activities of daily life and quality of life in young stroke patients. in order to prevent or at least reduce post-stroke cognitive decline, the mechanisms underlying the decline need to be further elucidated, to eventually develop new preventive and therapeutic approaches. t-cell activation is associated with destruction of brain tissue. in neurodegenerative diseases that primarily impair cognitive functions, e. g., alzheimers disease, t-cells were identified as important mediators of disease pathology. activation of cells of the adaptive immune system, most importantly t-cells, has been also investigated in experimental stroke. here, these cells significantly contribute to secondary brain tissue damage. stroke is associated with massive changes of the central and peripheral immune response. the investigators and other groups demonstrated that despite an overall lymphopenia, t-cells are functionally intact and pro-inflammatorily polarized, for at least two weeks post-stroke. depletion of t cells has been shown to reduce infarct volume and to improve outcome in mice post-experimental stroke.

Eligibility criteria:
inclusion criteria * acute stroke that occurred within the last 72 hours as defined by acute neurological deficit in combination with an acute ischaemic infarct as documented by either a "diffusion weighted imaging" (dwi)-positive lesion on mr imaging or a new lesion on a ct scan; only cortical/subcortical infarcts will be included * age \> 18; ≤ 55 * provision of written informed consent or through a surrogate as appropriate * willingness to participate in follow-up * national institute of health stroke scale score (nihss) ≥ 4 * german as first language (neuropsychological tests and cut-offs developed for native speakers) exclusion criteria * patients are excluded if they are not able to give informed consent due to severe cognitive deficits * signs of infection on admission (c-reactive protein ≥ 50 mg/l) * patients receiving immunosuppressive drugs or diagnosed with a malignancy or severe neurological diseases other than stroke (e.g., neurodegenerative movement disorders, motoneuron diseases)
&#34;comparison of shockwave application on the sole of the foot vs. the back of the leg in the treatment of plantar fasciitis: a clinical trial.&#34;

Conditions: Plantar Fasciitis

Summary: the study focuses on plantar fasciitis, one of the most common causes of non-traumatic foot and ankle pain, with an estimated prevalence of 10%. its objective is to evaluate the effectiveness of shock wave therapy applied along the course of the sciatic nerve in treating plantar fasciitis, comparing its effects on pain, foot-ankle functionality, and quality of life. forty-eight subjects will be recruited and randomly assigned to two groups: one will receive local shock wave therapy, while the other will receive therapy along the sciatic nerve. data will be collected at four points in time: before the intervention, one week after, one month after, and three months after, with blinded data collection. pain, foot-ankle functionality, and quality of life will be measured. data analysis will be performed using spss 29.0, applying anova and other tests depending on the normality of the data. differences will be estimated with a 95% confidence interval and a p-value \&lt; 0.05.

introduction: plantar fasciitis is one of the most common causes of non-traumatic ankle-foot pain. the exact prevalence is unknown, but it is estimated to be around 10%. objective: to evaluate the efficacy of applying shock waves along the course of the sciatic nerve in the treatment of plantar fasciitis and its effect on pain, as well as to assess changes in ankle-foot functionality and quality of life. material and methods: forty-eight subjects who meet the inclusion criteria will be recruited and randomly assigned to each intervention group. the control group will receive local shock wave therapy, while the experimental group will receive shock wave therapy along the course of the sciatic nerve. data collection: data will be collected at four different times: before the intervention, one week after, one month after, and three months after. the data collection will be carried out by a team member who will be blinded to the group to which the subject belongs. the dependent variables to be measured are pain (vas scale), ankle-foot functionality (ffi), and quality of life (sf12). data analysis: the data analysis will use spss 29.0. normality of variables will be assessed, and descriptive analyses will be conducted. initial homogeneity between groups will be compared, and anova and other tests will be applied according to normality and homoscedasticity. differences and percentage changes will be calculated, estimating effect size, with a 95% ci and p \&lt; .05.

Eligibility criteria:
inclusion criteria: having been diagnosed with plantar fasciitis, experiencing pain related to the condition for at least 1 month, and being between 18 and 65 years of age. exclusion criteria: being pregnant, having a pacemaker, presenting with rheumatoid arthritis, or having coagulation disorders.

Keywords: plantar fasciitis, shockwaves, sciatic nerve.
safety and efficacy of anecortave acetate in patients with open-angle glaucoma

Conditions: Open-angle Glaucoma

Summary: the purpose of this study was to evaluate the safety and intraocular pressure (iop)-lowering efficacy of anecortave acetate for treatment of elevated iop in patients with open-angle glaucoma.


Eligibility criteria:
inclusion criteria: * diagnosis of open-angle glaucoma; * other protocol-defined inclusion criteria may apply. exclusion criteria: * pseudoexfoliation; * pigment dispersion component; * other protocol-defined exclusion criteria may apply.

Keywords: glaucoma
comparison of immediate vs gradual switch to divalproex in adults with intellectual disability

Conditions: Epilepsy

Summary: the purpose of this study is to determine whether there is any difference in side effects experienced by individuals with intellectual disorders taking depakote dr (immediate release form) when they are switched to the extended release form (er) overnight versus when they switch more gradually over a week.

considering that there are potential advantages to once-daily depakote extended release in terms of decreased side effects, decreased medication errors and patient compliance, there is a need to determine the best method of conversion from multiple-daily dose delayed release depakote to once-daily for subjects with epilepsy bipolar disorder or behavior disorders.

Eligibility criteria:
inclusion criteria: * patients currently taking divalproex direct release for any seizure and/or behavior disorder * patients with intellectual disability * other medications for co-morbid disease are permitted, provided no plans for changes in medication used for the treatment of the disorder are expected exclusion criteria: * patients with a recent history of status epilepticus in the past 6 months * seizures in the past 3 months * patients with acute illness requiring changes in concurrent drugs * patients unwilling to change from their present direct release divalproex to divalproex extended release * patients that do not have a reliable caregiver * patients with lack of verbal expressive speech

Keywords: intellectual disabilities development disabilities behavior disorders stable epilepsy
sensor: study to investigate cinacalcet treatment in haemodialysis patients with secondary hyperparathyroidism

Conditions: Secondary Hyperparathyroidism; End Stage Renal Disease

Summary: the purpose of this study is to demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.


Eligibility criteria:
inclusion criteria: - ckd patients requiring dialysis (hd, hdf, hf) for at least 1 month before enrolment - an ipth determination within 14 days before randomisation must be greater than or equal to 300 pg/ml (bipth greater than or equal to 150 pg/ml) - a serum calcium determination (corrected for calcium) within 14 days before randomisation must be greater than or equal to 8.4 mg/dl \[2.1 mmol/l\] exclusion criteria: - have an unstable medical condition, defined as having been hospitalised, other than for dialysis vascular access revision, within 30 days before day 1, or otherwise unstable in the judgment of the investigator - are currently breast-feeding - are performing peritoneal dialysis - have had a parathyroidectomy in the 3 months before day 1 - have a gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets

Keywords: clinical trial amgen secondary hyperparathyroidism (shpt) dialysis end stage renal disease (esrd) kdoqi cinacalcet
genetic diagnosis in congenital cataracts

Conditions: Congenital Cataract

Summary: the prediction of genetic risk in congenital cataract patients has great clinical significance. in this trial, the investigators aim to screen the causative variants from 115 unrelated bilateral congenital cataract patients enrolled consecutively, describe novel and recurrent variants, analyze the factors affecting genetic diagnostic yield, and explore potential phenotype-genotype correlation.

determining whether the disease is hereditary and the precise genetic cause of congenital cataract has great clinical significance in guiding genetic counseling and improving clinical care pathway. varying among studies, genetic causes account for 8.3-85% of congenital cataracts because of the difference in ethnic background, genetic screening techniques used, the percentage of patients with bilateral cataracts, with a family history, and with syndromic disease. a phenotype-genotype correlation may be used to predict the causative genes, and the involvement of other tissues and organs based on the appearance of the lens. in addition, it can be used to improve our understanding of lens biology. a phenotype-genotype correlation is difficult to establish because of the genotypic and phenotypic heterogeneity of congenital cataracts. in this trail, the investigators aim to screen the causative variants from 115 unrelated bilateral congenital cataract patients enrolled consecutively, describe novel and recurrent variants, analyze the factors affecting genetic diagnostic yield, and explore potential phenotype-genotype correlation. facial and anterior eye segment photographs, pre- and post-operative ocular parameters, and medical and family histories were recorded. bioinformatics analysis was performed using whole-exome sequencing data. statistical and correlation analyses were performed using the basic characteristics, deep phenotype, and genotype data.

Eligibility criteria:
inclusion criteria: 1. the participant with bilateral congenital cataract; 2. have signed a consent form. . exclusion criteria: 1. the participant not identified with congenital cataract; 2. the participant with unilateral congenital cataract. -

Keywords: congenital cataract genetic diagnosis phenotype-genotype correlation
echelon-2: a comparison of brentuximab vedotin and chp with standard-of-care chop in the treatment of patients with cd30-positive mature t-cell lymphomas

Conditions: Anaplastic Large-Cell Lymphoma; Non-Hodgkin Lymphoma; T-Cell Lymphoma

Summary: this is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with chp with the standard-of-care chop in patients with cd30-positive mature t-cell lymphomas.


Eligibility criteria:
inclusion criteria: * patients with newly diagnosed, cd30-positive mature t-cell lymphomas * fluorodeoxyglucose (fdg)-avid disease by pet and measurable disease of at least 1.5 cm by ct * eastern cooperative oncology group (ecog) performance status less than or equal to 2 exclusion criteria: * history of another primary invasive malignancy that has not been in remission for at least 3 years * current diagnosis of primary cutaneous cd30-positive t-cell lymphoproliferative disorders and lymphomas or mycosis fungoides * history of progressive multifocal leukoencephalopathy (pml) * cerebral/meningeal disease related to the underlying malignancy

Keywords: antibodies, monoclonal antibody-drug conjugate antigens, cd30 drug therapy hematologic diseases lymphoma monomethyl auristatin e lymphoma, t-cell lymphoma, non-hodgkin lymphoma, large-cell, anaplastic
effect of indacaterol on inspiratory capacity and lung function in patients with copd versus placebo and formoterol

Conditions: COPD

Summary: the purpose of this study is to assess the change in inspiratory capacity and lung function in patients with chronic obstructive pulmonary disease when treated with indacaterol compared to placebo and formoterol.


Eligibility criteria:
inclusion criteria: * male and post-menopausal female adults aged 40-80 years inclusive. * patients with a clinical diagnosis of copd according to the global initiative for chronic lung disease (gold) guidelines (2005) * smoking history of at least 10 pack years (either smokers or ex-smokers). * able to perform reproducible spirometry maneuvers. * able to communicate well with the investigator, to understand and comply with the requirements of the study. understand and sign the written informed consent. exclusion criteria: * copd exacerbations within 6 weeks prior to dosing * concomitant lung disease such as asthma, requirement for long term oxygen treatment or history of lung reduction surgery. * medical conditions that would interfere with the performance of spirometry or may pose a potential hazard from performing spirometry. * any other medical condition that in the opinion of the investigator may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from being in the study, e.g. uncontrolled hypertension, unstable ischemic heart disease. * participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations. other protocol-defined inclusion/exclusion criteria may apply

Keywords: inspiratory capacity, fev1, copd
can contrast enhanced spectral mammography (cesm) reduce the number of benign biopsies for calcifications without negatively impacting on detection/diagnosis of clinically significant calcifications

Conditions: Mammography

Summary: women who attend for their screening mammogram will be recalled if an abnormality is detected on the screening mammogram. calcifications account for 20% of the women recalled to second stage screening. currently there is no effective imaging tool to determine if the calcifications are cancer or not. therefore, 90% of women will be subjected to a biopsy. 25-30% of the biopsies will show cancer. contrast enhanced spectral mammography (cesm) is where contrast is given and then a mammogram performed. the theory is that high risk dcis and invasive cancers have an increased blood supply and will therefore enhance more than benign lesions within the breast. if cesm can identify calcifications that are cancerous then we maybe able to reduce the number of women who have benign biopsies. this is patient focused as women would not require a biopsy and be able to be reassured at the same visit. this is also a cost-saving for the trust by reducing unnecessary biopsies. this also supports the findings of the marmot review by aiming to reduce harm by over-diagnosis.


Eligibility criteria:
inclusion criteria: 1. recalled for second stage screening due to microcalcifications on the mammogram 2. renal function is within normal limits 3. no known allergies to contrast 4. able to give informed consent exclusion criteria: 1. known allergy to contrast 2. renal impairment 3. unable to provide informed consent 4. having radioactive iodine treatment for hyperthyroidism
comparison of immediate versus delayed removal of urinary catheter following elective cesarean section

Conditions: Urinary Catheter; Cesarean Section; Urinary Infection

Summary: the objective this trial is to compare immediate and 12 hours postoperative removal of urinary catheter after elective cesarean section; and whether early removal is associated with lower risk of urinary infection compared with delayed catheter removal.


Eligibility criteria:
inclusion criteria: - women admitted to the prenatal wards for primary or repeat elective cesarean section exclusion criteria: * urinary infection (assessed clinically and by midstream urinalysis), * significant vaginal bleeding, * severe pre-eclampsia or eclampsia and/or any other conditions requiring postoperative monitoring of urinary output, and * contraindications for general anesthesia.
study to evaluate the safety and tolerability of a new drug named lu af20513 in patients with mild alzheimer's disease

Conditions: Alzheimer Disease

Summary: the purpose of this study is to determine if multiple immunizations with lu af20513 is tolerable and safe in patients with mild alzheimer's disease.


Eligibility criteria:
main inclusion criteria: * the patient has a diagnosis of probable alzheimer's disease (ad) consistent with the national institute of neurological and communicative disorders and stroke and the alzheimer's disease and related disorders association (nincds-adrda) criteria * the patient has a pattern of antibodies in cerebrospinal fluid (csf) consistent with an amyloid plaque load * the patient is a man or a woman, and between ≥60 and ≤85 years of age * the patient has an mri (performed within 3 months before screening) with results consistent with the diagnosis of probable ad * the patient has a mild severity of dementia * the patient has a knowledgeable and reliable caregiver who will be available and able to: accompany the patient to all clinical visits, monitor ire after each immunization, and participate with the patient at all phone visits during the study ad * patients must have completed part a before being eligible for continued immunisations in part b main exclusion criteria: * the patient has evidence of mixed etiology of dementia (i.e. absence of other neurodegenerative, neuroinflammatory or cerebrovascular disease, or another neurological, mental or systemic disease or condition likely contributing to cognitive decline) * the patient has clinical and radiological findings that fulfil the standards of the national institute of neurological disorders and stroke and association internationale pour la recherché et l'enseignement en neurosciences (ninds-airen) criteria for vascular dementia * the patient has a diagnostic and statistical manual of mental disorders, 4th edition, text revision (dsm-5-tr) axis i disorder other than ad; including amnestic disorders, delirium, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, post-traumatic stress disorder and/or cognitive disorder not otherwise specified, (note: patients may be included if treated with a stable dose of antidepressants for at least 2 months and not fulfilling dsm-5-tr criteria for depression at screening) * the patient's eligibility mri scan (1.5t) shows findings that correspond to more than 4 brain micro haemorrhages * the patient has extensive white matter lesions as shown on the screening mri scan (1.5t) other protocol-defined inclusion and exclusion criteria do apply
efficacy of rtms on pain following stroke.

Conditions: Stroke

Summary: pain is a common symptom experienced by people following stroke and can significantly interfere with participation in the activities of daily living and adversely affect health-related quality of life. repetitive transcranial magnetic stimulation (rtms) promotes the modulation of brain activity and its prolonged and continuous application can effect plastic modification. combining rtms with rehabilitation treatment for primary motor cortex activation (using gloreha® device) may have effect in reducing pain in stroke survivors. this is a pilot randomized control trial to test the effects of rtms in stroke-related pain rehabilitation, its efficacy on pain, upper limb function, sensory function and autonomy in daily livings activities. furthermore, we will explore the effects on pressure pain threshold, cortical excitability and eeg recording.


Eligibility criteria:
inclusion criteria: * diagnosis of first stroke verified by brain imaging \< 6 months * pain defined as a constant or intermittent sensory symptom with unpleasant feelings or pain and a minimum score of 3 points on the numeric rating scale (nrs) for pain perception exclusion criteria: * medical conditions likely to interfere with the ability to safely complete the study protocol * cognitive functioning to give informed consent identified by a mini-mental status examination (mmse) score ≥ 24/30 * intracranial metal implants * history of seizures or epilepsy * severe cardiopulmonary, renal, and hepatic diseases * pregnancy

Keywords: pain rtms rehabilitation